集团简介
爱尔眼科创立于 2002 年，医疗网络布局亚洲、欧洲和北美洲，于 2009 年在中国深圳上市（股票代码：300015）；公司在欧洲、东南亚的分支机构分别在西班牙马德里（CBAV.MC）、新加坡（SGX:40T）上市。截至 2023 年 12 月 31 日，爱尔眼科品牌医院、眼科中心及诊所在全球范围内共有 881 家。其中，中国内地 750家（包括上市公司旗下 439 家，产业并购基金旗下 311 家），中国香港 8 家，在海外布局突破 123 家眼科诊所， 包括美国 1 家，欧洲 108 家，东南亚 14 家。
Aier Eye Hospital, established in 2002, has
a vast medical presence in Asia, Europe, and North America. Aier Eye Hospital
was listed in 2009 in Shenzhen, China (Stock code: 300015), and its branches in
Europe and Southeast Asia were listed in Madrid, Spain (CBAV.MC) and Singapore
(SGX:40T), respectively. As of December 31, 2023, there were 881 eye hospitals,
eye centers and clinics under Aier brand. Among them, there were 750 in the
Chinese Mainland (including 439 under the Company and 311 under M&A Funds),
8 in Hong Kong, China, and more than 123 located overseas, including 1 in the
United States, 108 in Europe, and 14 in Southeast Asia.
作为全球化眼科医疗集团，爱尔眼科现阶段坚持以国内医疗发展为主线，国内国际双线并举，共同进步的战略方针，引进和吸收国际同步的眼科技术与医疗管理理念，以专业化、规模化、科学化的模式助推中国眼科行业的发展，力争提升中国眼科医疗的整体水平，辐射全球。通过不断实践，在引进吸收国际先进的医疗管理经验的基础上，爱尔眼科成功探索出了一套适应中国国情和市场环境的眼科医院连锁经营管理模式——“分级连锁”，促进核心医疗资源的高效利用，有效对接国家医改政策“分级诊疗、双向转诊”，真正使老百姓享受到优质、可及的医疗资源。
Domestic market is the core business of
AIER and international market plays a more and more important role in our
global strategy. We are committed to introducing and absorbing the cutting-edge
technology and advanced management concepts, as well as to contributing to the
evolution of China's ophthalmology market, in a specialized, scaled-up and
scientific way.
AIER has successfully explored the business
model in line with China’s national and market condition through continuous
practice- the “hierarchical chain”- to fully utilize advantages in talent,
technology and management so as to achieve better clinical outcome, to improve service
standard and to optimize communication between patients and medical personnel.
科研创新、人才培养是长远发展的基石，爱尔眼科不断加大科研投入，大力支持开展前沿性、原创性的眼科学术研究，全力推进全球化平台上的眼健康生态圈战略。自2013年与中南大学联合成立中南大学爱尔眼科学院，正式开启校企合作的创新探索以来，爱尔眼科已陆续推动了与多家国内外知名高校的战略合作，充分发挥企业和高校的独特优势，在医院共建、人才培养、师资队伍建设、教学科研等领域展开深入合作，联手共建顶尖眼科医教研平台，为社会培养更多优秀的眼科医学人才，真正地为中国眼科学和视觉科学的创新发展贡献智慧与力量。
Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.
Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.
AIER and the universities are sharing the
same goal to build an integrated education and research platform by leveraging
the strengths of “Good Company” and “Famous University” through in-depth
collaboration in areas of hospital co-management, talent and faculty training,
academic development and scientific research, so as to train excellent
ophthalmic talents for the community, as well as to contribute our wisdom and
power to the evolution of the ophthalmology and vision science in China.
在此基础上，爱尔眼科持续打造立体化科研平台，截止目前已在全国范围内构建起“八所、二站、二基地、三中心”的创新型科教研一体化平台。“八所”：爱尔眼科研究所、爱尔眼视光研究所、爱尔角膜病研究所、爱尔屈光研究所、爱尔视网膜研究所、爱尔青光眼研究所、爱尔白内障与人工晶状体研究所、武汉爱尔眼科研究所。获批设立“二站”：国家博士后科研工作站、院士专家工作站；“二基地”：眼视光国际科技合作基地、“海智计划”工作基地；“三中心”：眼视光工程技术研究中心、眼表疾病临床医学研究中心、企业技术中心；联合共建“爱尔眼科-中科院计算所数字眼科联合实验室”等创新平台。
Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.
“Eight Institutes” refers to Eye Institute,
Optometry & Visual Science Institute, Keratoconus Institute, Refractive
Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER
Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National
Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial
Workstation, which was established after approval; “Two Bases” refers to Hunan
International Optometry Science and Technology Cooperation Base and HOME
Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry
Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical
Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile
various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint
Laboratory” were jointly established.
上市十年之际，爱尔眼科以“创新驱动，科技爱尔”为指导方针，提出三大战略目标。一是要将眼科医疗服务网络覆盖到中国的广大城乡县域，让老百姓在家门口就能享受到高质量的、可及的眼科医疗服务，助推健康中国战略。二是通过打造世界级及国家级的眼科医学中心，切实提高中国眼科医疗技术水平，赶超世界先进水平。三是通过全球化布局，医、教、研、产、投全面协同发展，推动人类眼科学与视觉科学进步。
On the 10th Anniversary of listing, AIER
took “Innovation Driven and Technology Empowered” as the guideline and proposed
three strategic goals. The first goal is to expand the medical service network
into vast urban and rural areas, enabling patients to experience convenient and
high-quality ophthalmic medical service, implementing the strategy of “Healthy
China”. The second goal is to continuously improve ophthalmic medical
technology in China and to be recognized as world-level excellence by building
up world-class and national-level ophthalmic medical center. The last but not
the least goal is to promote advancement of human ophthalmology and visual
science through global footprint as well as coordinated development of
medicine, education, research, industrial and investment.
在二十年的创业发展历程中，爱尔眼科凝聚和培养了一批经验丰富、具有开拓创新精神的管理团队和医术精良、治学严谨的眼科专家和医生团队。截至目前，爱尔眼科医院集团及旗下全球员工总数达50,000余人，其中眼科医生及视光师总数(含海外) 7,100余人，包括一大批博士生导师、硕士生导师、博士、博士后、留学欧美的学者以及临床经验丰富的核心专家。
Through the past 20-year growth and
expansion, AIER has attracted and cultivated a group of experienced management
team with innovative spirit, as well as a team of well-trained ophthalmologists
and doctors with excellent medical skills and rigorous scholarship. At present,
AIER has more than 50,000 employees worldwide. Among them, 7,100 are
ophthalmologists and optometrists (including domestic and overseas), with a big
group of doctoral supervisors, master supervisors, doctors, post-doctors,
oversea scholars, and even core experts with extensive clinical experiences.
爱尔眼科的发展壮大始终“以爱心致力于人类的眼健康”为初心，以“使所有人，无论贫穷富裕，都享有眼健康的权利”为使命，坚持“以患者为中心”，追求社会责任和自身发展的和谐统一。通过开创性的“交叉补贴”模式，在为患者提供更高品质的眼科医疗服务的同时，全面开展防盲治盲工作、投身社会公益、帮助弱势群体，积极联合社会各界力量，推动中国防盲事业乃至国民眼健康事业的全面发展。2018年、2020年蝉联第十届、第十一届中国政府最高慈善奖项“中华慈善奖”、荣获中国公益年会“中国公益企业奖”、“最佳社会责任上市公司”、“湖南慈善奖”等荣誉。同时积极响应国家号召，作为中国代表企业牵头参与“一带一路光明行”、“湄公河光明行”等公益活动，获得组织者、受援国政府和患者的高度好评，逐步发展成为全球慈善公益活动的一张名片。
The growth of AIER always sticks to the
original intention and mission of “Enabling everyone, no matter rich or poor,
has the right to eye health”. We are committed to the bright future of all
human beings, insisting on “patient-oriented” principle, and pursuing the
harmonious unity of social responsibility and self-development. By adopting the
pioneering “Cross Subsidy Model”, while offering our patients higher-quality
ophthalmic medical service, AIER also comprehensively carries out blindness
prevention and treatment, devotes to public welfare, helps vulnerable groups,
and actively unites all forces from society, promoting the comprehensive
development of China’s blindness prevention and even the eye health career of
citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China
Charity Award” by Chinese Government. Besides, we were also awarded many other
honors, such as “China Public Welfare Enterprise Award”, “Best Socially
Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER
responded positively to the national appeal and took the lead in different
public benefit activities such as “The Belt and Road Brightness Campaign” and
“Mekong Brightness Campaign”, winning unanimous praise from organizers, aid
recipient governments and patients. In this way, AIER has been gradually regarded
as a representative of global philanthropy activities.
爱尔眼科连续多年被权威机构评为“中国最受投资者尊重的上市公司前十强”，蝉联中国品牌节“华谱奖”，荣获“最佳持续投资价值奖”、“中国上市公司最佳股东回报奖”、“中国上市公司实业贡献大奖”等多项殊荣，成功入选沪深300指数股、MSCI中国大盘指数成份股等。
AIER has been rated as “Top 10 Most Valued
Public Company in China” by authoritative institutions for multiple consecutive
years. We won the “China Spectrum Award” of China Brand Festival consecutively
and many other honors, including “Best Sustainable Investment Value Award”,
“Chinese Public Company Best Shareholder Return Award”, and “Chinese Public
Company Industrial Contribution Award”, etc. At the same time, AIER was also
successfully selected as CSI 300 Index Stock and MSCI China Index Constituent
Stock, etc.